We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Breast Cancer Test Links Immune Hotspots to Better Survival

By LabMedica International staff writers
Posted on 16 Mar 2015
A new test has been developed that can predict the survival chances of women with breast cancer by analyzing images of hotspots where there has been an intense immune reaction to a tumor.

The test that combines automated histological image processing with methods of spatial statistics could assess whether a woman's immune system is holding a cancer at bay and pick out those who will need intensive treatment to combat their more aggressive disease.

Image: The ScanScope digital slide scanner (Photo courtesy of Aperio Technologies).
Image: The ScanScope digital slide scanner (Photo courtesy of Aperio Technologies).

Scientists at The Institute of Cancer Research (London, UK) and their colleagues analyzed tumor samples from 245 women with a type of breast cancer called estrogen receptor negative (ER negative), which is particularly hard to treat. The team split women with breast cancer into two groups based on the numbers of immune hotspots spots within their tumors.

The tumor sections were scanned using ScanScope TX Scanner (Aperio Technologies; Vista, CA, USA) with × 20 magnification and digitized for image analysis. Stained frozen tumor section images for 245 ER-negative breast cancer patients were analyzed using their automated cell classification pipeline CRImage. The cell classification and location data were used as input for Getis–Ord hotspot analysis to enable the automated detection of statistically significant spatial clusters.

The scientists found that images of hotspots where immune cells were spatially clustered together around breast cancer cells provided a better measure of immune response than simply the numbers of immune cells within a tumor. Women whose cancers had a high number of spots lived an average of 91 months before their cancer spread, compared with just 64 months for those with a low number of spots. The test is the first objective method of measuring the strength of a patient's immune response to their tumors. Its automated analysis could complement existing methods where pathologists examine tumor samples under the microscope to gain a sense of whether there is a strong immune response.

Yinyin Yuan, PhD, the team leader and senior author, said, “We have shown that to measure the strength of an immune response to a cancer, we need to assess not just how many immune cells there are, but whether these are clustered together into cancer-busting hotspots. By analyzing the complex ways in which the immune system interacts with cancer cells, we can split women with breast cancer into two groups, who might need different types of treatment.” The study was published on February 27, 2015, in the journal Modern Pathology.

Related Links:
The Institute of Cancer Research  
Aperio Technologies  



Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Automated Blood Typing System
IH-500 NEXT
New
Silver Member
Benchtop Image Acquisition Device
Microwell Imager
New
Silver Member
Oncology Molecular Diagnostic Test
BCR-ABL Dx ELITe MGB Kit

Latest Pathology News

New Microscopy Method Enables Detailed Whole Brain 3D RNA Analysis

AI Model Identifies Signs of Disease Faster and More Accurately Than Humans

New Barcode Technology to Help Diagnose Cancer More Precisely